This post was originally published on this site
In an emailed response on Wednesday, Johnson & Johnson confirmed plans to exit some of its vaccine research and development programmes, which it said it had initially disclosed in its 2023 second-quarter results.
“We also continually assess our global footprint, including in the Netherlands, to ensure it meets our current and evolving scientific needs,” Johnson & Johnson said.
De Telegraaf reported that 2,500 people worked at Janssen in the Netherlands, a quarter of which were in the section specialising in infectious diseases and vaccines.
It is not clear how many jobs are at risk.